Evidence map›Paper›PMID 29354491›Full record

ReviewTranslational andrology and urology2017

Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction.

Karl H Pang, Francesco Esperto, Aidan P Noon, EAU Young Academic Urologists-Urothelial Cancer Working party

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational andrology and urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Ceramide Transfer Protein (CERT): An Overlooked Molecular Player in Cancer.International journal of molecular sciences · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Bladder Cancer at the time of COVID-19 Outbreak.International braz j urol : official journal of the Brazilian Society of Urology · 2020
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Karl H PangAcademic Urology Unit, University of Sheffield, Sheffield, UK.
Francesco EspertoDepartment of Urology, Royal Hallamshire Hospital, Sheffield, UK.
Aidan P NoonDepartment of Urology, Royal Hallamshire Hospital, Sheffield, UK.
EAU Young Academic Urologists-Urothelial Cancer Working party
Royal Hallamshire Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) is a common disease in both sexes and majority of cases present as non-muscle invasive BC (NMIBC). The percentage of NMIBC progressing to muscle invasive BC (MIBC) varies between 25% and 75% and currently there are no reliable biomarkers that may predict the outcome of high-risk (HR) NMIBC. Whilst The Cancer Genome Atlas (TCGA) project has identified genetic alteration in MIBC using next-generation sequencing (NGS), genetic data in HR-NMIBC outcome prediction using this new technology are limited. We reviewed data on NGS performed on DNA and RNA extracted from tissue, plasma and urinary samples obtained from patients with NMIBC. Analysis on different specimens revealed genetic alterations and microRNA alterations in common oncogenic pathways such as gene expression (

Indexed as

biomarkerNext-generation sequencing (NGS)non-muscle invasive bladder cancer (NMIBC)

Identifiers

PMID29354491
PMCPMC5760392
OpenAlexW2767386373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.